American depositary receipt

Eco Wave Power Announces Participation in Credit Suisse Tech Conference, and in a Fireside Chat with Jeffery Campbell, Alternative Energy Analyst from Alliance Global Partners

Retrieved on: 
Friday, December 2, 2022
European Commission Investment Plan for Europe, WAVE, Energy, Climate change, United Nations, Port of Los Angeles, European Commission, First Nations in Ontario, Conference, Virtual, Framework Programmes for Research and Technological Development, Innovation, American depositary receipt, Port, Pioneer Technology Center, Innovate UK, Renewable energy

AGP Fireside Chat, December 13, 2022: Jeffrey Campbell, Managing Director, Alternative Energy and Energy Research at Alliance Global Partners, will interview Ms. Braverman at 11 a.m.

Key Points: 
  • AGP Fireside Chat, December 13, 2022: Jeffrey Campbell, Managing Director, Alternative Energy and Energy Research at Alliance Global Partners, will interview Ms. Braverman at 11 a.m.
  • Eco Wave Power's mission is to assist in the fight against climate change by enabling commercial power production from the ocean and sea waves.
  • Eco Wave Power received funding from the European Union Regional Development Fund, Innovate UK and the European Commission's Horizon 2020 framework program.
  • Eco Wave Power's American Depositary Shares (WAVE) are traded on the Nasdaq Capital Market.

Eco Wave Power Announces Participation in Credit Suisse Tech Conference, and in a Fireside Chat with Jeffery Campbell, Alternative Energy Analyst from Alliance Global Partners

Retrieved on: 
Friday, December 2, 2022
European Commission Investment Plan for Europe, WAVE, Energy, Climate change, United Nations, Port of Los Angeles, European Commission, First Nations in Ontario, Conference, Virtual, Framework Programmes for Research and Technological Development, Innovation, American depositary receipt, Port, Pioneer Technology Center, Innovate UK, Renewable energy

AGP Fireside Chat, December 13, 2022: Jeffrey Campbell, Managing Director, Alternative Energy and Energy Research at Alliance Global Partners, will interview Ms. Braverman at 11 a.m.

Key Points: 
  • AGP Fireside Chat, December 13, 2022: Jeffrey Campbell, Managing Director, Alternative Energy and Energy Research at Alliance Global Partners, will interview Ms. Braverman at 11 a.m.
  • Eco Wave Power's mission is to assist in the fight against climate change by enabling commercial power production from the ocean and sea waves.
  • Eco Wave Power received funding from the European Union Regional Development Fund, Innovate UK and the European Commission's Horizon 2020 framework program.
  • Eco Wave Power's American Depositary Shares (WAVE) are traded on the Nasdaq Capital Market.

BIOPHYTIS ORGANISES A WEBCAST WITH KEY OPINION LEADERS (KOL) ON THE PHASE 2-3 COVA STUDY RESULTS OF SARCONEOS (BIO101) IN THE TREATMENT OF PNEUMONIA IN COVID-19 PATIENTS AT RISK OF RESPIRAT

Retrieved on: 
Thursday, December 1, 2022
COVID-19, Rio Preto, ITT, Hospital, Pneumonia, American depositary receipt, Euronext Growth, Risk, Duchenne muscular dystrophy, MI, Patient, Ageing, Pandemia, Ticker, Q&A, MD, Security (finance), Beaumont Hospital, DMD, ADSS, Internet, CET, Death, PP, Therapy, Sarcopenia, KOL, Trial of the century, Critical care, Safety, Principal, Pharmaceutical industry, Paulo, Medicine

The regulatory development of Sarconeos (BIO101) targeting conditional and emergency use marketing authorisations will start in 2023.

Key Points: 
  • The regulatory development of Sarconeos (BIO101) targeting conditional and emergency use marketing authorisations will start in 2023.
  • As a reminder, the COVA clinical study (identifier clinicaltrials.gov: NCT04472728) is an international, multi-centre, double-blind, placebo-controlled, group-sequential and adaptive two-part study.
  • It is a phase 2-3 study evaluating Sarconeos (BIO101) in patients aged 45 years and older, hospitalised with severe respiratory manifestations of COVID-19.
  • Part 2 of the COVA study is a randomised phase 3 study investigating the safety and efficacy of Sarconeos (BIO101) on respiratory function in patients.

Sims Limited Signs Global Agreement on Climate Policy Engagement

Retrieved on: 
Wednesday, November 30, 2022
Greenhouse, Culture, Paris, Heart, Environment, Atmosphere, COP27, Organization, Conference, American depositary receipt, Climate change, Australian Securities Exchange, ASX, Policy, Climate, Movement, United Nations Climate Change conference, 2015 United Nations Climate Change Conference, LMS, Electricity, Carbon, Mining, USOTC, Corporate Knights, Renewable energy, Earth

SYDNEY, Nov. 30, 2022 /PRNewswire/ -- Sims Limited (ASX: SGM), a global leader in sustainability and an enabler of the circular economy, and joint venture partner LMS Energy, one of Australia's largest emissions reducers and most experienced landfill biogas companies, today announced that they are the latest signatories of the Action Declaration on Climate Policy Engagement. The declaration, a joint initiative of Corporate Knights and the Global 100 Council, was announced recently at COP27, the 2022 United Nations Climate Change Conference in Sharm el-Sheikh, Egypt.

Key Points: 
  • This action garnered the support of more than 50 global companies that are committed to ensuring their climate policy engagement, and that of their industry associations, helps to address climate change, not stall it.
  • It brings together corporate leaders who are committed to improving publicprivate policy engagement to move the world toward the clean economy needed to address climate change.
  • "This year, Sims Limited assessed the climate policy positions of our industry associations as part of our shareholder-endorsed climate action plan and disclosed the results," said Alistair Field, chief executive officer and managing director at Sims Limited.
  • Sims Limited joins more than four dozen global companies that are also committed to ensuring their climate policy engagement supports governments in addressing climate change.

Sims Limited Signs Global Agreement on Climate Policy Engagement

Retrieved on: 
Wednesday, November 30, 2022
Greenhouse, Culture, Paris, Heart, Environment, Atmosphere, COP27, Organization, Conference, Multimedia, American depositary receipt, Climate change, Australian Securities Exchange, ASX, Policy, Climate, Movement, United Nations Climate Change conference, 2015 United Nations Climate Change Conference, LMS, Electricity, Carbon, Mining, USOTC, Corporate Knights, Renewable energy, Earth

SYDNEY, Nov. 30, 2022 /PRNewswire/ -- Sims Limited (ASX: SGM), a global leader in sustainability and an enabler of the circular economy, and joint venture partner LMS Energy, one of Australia's largest emissions reducers and most experienced landfill biogas companies, today announced that they are the latest signatories of the Action Declaration on Climate Policy Engagement. The declaration, a joint initiative of Corporate Knights and the Global 100 Council, was announced recently at COP27, the 2022 United Nations Climate Change Conference in Sharm el-Sheikh, Egypt.

Key Points: 
  • This action garnered the support of more than 50 global companies that are committed to ensuring their climate policy engagement, and that of their industry associations, helps to address climate change, not stall it.
  • It brings together corporate leaders who are committed to improving publicprivate policy engagement to move the world toward the clean economy needed to address climate change.
  • "This year, Sims Limited assessed the climate policy positions of our industry associations as part of our shareholder-endorsed climate action plan and disclosed the results," said Alistair Field, chief executive officer and managing director at Sims Limited.
  • Sims Limited joins more than four dozen global companies that are also committed to ensuring their climate policy engagement supports governments in addressing climate change.

O2MICRO INTERNATIONAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of O2Micro International Limited - OIIM

Retrieved on: 
Wednesday, November 30, 2022
Class Action Lawsuit, Professional Services, Legal, ADS, American depositary receipt, KSF, Sale

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Key Points: 
  • Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of O2Micro International Limited (NasdaqGS: OIIM) to FNOF Precious Honour Limited.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

AirNet Announces Results of Extraordinary General Meeting and ADS Ratio Change

Retrieved on: 
Wednesday, November 30, 2022
ADS, AirNet Express, American depositary receipt, Book, Bangladesh Securities and Exchange Commission, Holding company, Security (finance)

HOUSTON, Nov. 30, 2022 /PRNewswire/ -- AirNet Technology Inc., formerly known as AirMedia Group Inc. ("AirNet" or the "Company") (Nasdaq: ANTE), today announced that it held an extraordinary general meeting of shareholders on November 30, 2022.

Key Points: 
  • HOUSTON, Nov. 30, 2022 /PRNewswire/ -- AirNet Technology Inc., formerly known as AirMedia Group Inc. ("AirNet" or the "Company") (Nasdaq: ANTE), today announced that it held an extraordinary general meeting of shareholders on November 30, 2022.
  • The Share Consolidation will be effective at 5:00 P.M., on December 9, 2022 (U.S. Eastern time).
  • No physical action by ADS holders will be required to effect the ratio change, as the change will be effected on the books of the depositary.
  • The effect of the ratio change on the ADS trading price on the Nasdaq Capital Market is expected to take place at the open of business on December 12, 2022.

Freeline Receives Approval to Transfer to Nasdaq Capital Market

Retrieved on: 
Tuesday, November 29, 2022
Daimler Freeline, Fabry disease, American depositary receipt, Transgene, Gaucher's disease, Capsid, ADS, Research, EDGAR, AAV, Form 6-K, Fabry

LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline) today announced that it received approval from the Nasdaq Stock Market LLC (Nasdaq) to transfer the listing of its American Depositary Shares (ADSs) representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market.

Key Points: 
  • LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the Company or Freeline) today announced that it received approval from the Nasdaq Stock Market LLC (Nasdaq) to transfer the listing of its American Depositary Shares (ADSs) representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market.
  • The Nasdaq Capital Market is a continuous trading market that operates in the same manner as The Nasdaq Global Select Market.
  • All companies listed on The Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaqs corporate governance standards.
  • In connection with the transfer to the Nasdaq Capital Market, Nasdaq granted the Company an additional 180-day period (or until May 29, 2023) to regain compliance with the minimum bid price requirement.

Safe-T Group Reports growth of 109% Achieving Revenues of $13.6 Million for the First Nine Months of 2022, Exceeding Full-Year 2021 Revenues

Retrieved on: 
Tuesday, November 29, 2022
Microsoft Windows, Privacy, Growth, Proxy, Marketing, Loss, Computer security, American depositary receipt, Traction, Research, Nine Months, Tax, Android, TASE, Depreciation, Microsoft, Investment, Home After Three Months Away, Acquisition, Renewable energy, Bookkeeping, Financial services, Online shopping, Pharmaceutical industry, Satellite navigation device, Network equipment, Retail, Reinsurance, Adjustment

HERZLIYA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Safe-T Group Ltd. (Nasdaq: SFET) (TASE: SFET) (“Safe-T” or the “Company”), a global provider of cyber-security and privacy solutions to consumers and enterprises, today announced record financial results for the nine-month period ended September 30, 2022. 

Key Points: 
  • Gross profit for the nine-month period ended September 30, 2022 amounted to $7,360,000, an increase of 143% compared to the corresponding period in 2021.
  • During the third quarter we invested $1.2 million in costumer' acquisition, which has already returned 20% of the investment.
  • In the second quarter, the Company secured a $2 million non-dilutive credit line facility from United Mizrahi-Tefahot Bank Ltd.
  • Consecutive months of growth and business expansion:
    Enterprise privacy business turns profitable, and marks three record revenue months.

Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases

Retrieved on: 
Tuesday, November 29, 2022
US Foods, Laboratory, Australian Securities Exchange, Chemistry, Vitiligo, Inflammatory bowel disease, Anxiety, Patient, Doctor of Philosophy, Incidence, Environment, Addiction, Immune system, Skin, Pain, Pigment, ASX, OSA, Rheumatoid arthritis, FDA, Concussion, Food, Genomics, Sleep apnea, Traumatic brain injury, TBI, Cannabinoid, Disease, Patent, American depositary receipt, CDMO, Atopic dermatitis, Safety, Dermatitis, Acquisition, Contract research organization, Pharmacology, COPD, CBG, Asthma, U.S. FDA, Psoriasis, Bronchitis, Pharmaceutical industry, Vaccine, Cannabigerol, Cannabidiol, Eurofins Scientific, MD

A previous version of ReneCann was used in an in-human proof of concept study with dosing over a 6-week period.

Key Points: 
  • A previous version of ReneCann was used in an in-human proof of concept study with dosing over a 6-week period.
  • In the study, ReneCann reduced disease scores in patients with each of the target skin diseases.
  • ReneCann also has the potential to be assessed for efficacy in other diseases where topical application may provide a benefit over conventional oral dosed cannabinoid formulations.
  • Incannex is investigating the use of Eurofins to develop and manufacture additional drug candidates acquired via the acquisition of APIRx Pharmaceuticals.